What is it about?
How the duration of melatonin intervention differentially impacts cognition in patients with Alzheimer’s disease (AD)? Which severity classes of Alzheimer’s disease show the greatest benefit of melatonin treatment?
Featured Image
Photo by Robina Weermeijer on Unsplash
Why is it important?
We found AD patients receiving >12 weeks of melatonin treatment improved cognition. Importantly, melatonin treatment significantly improved MMSE score in mild levels of AD.
Perspectives
Read the Original
This page is a summary of: Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer’s disease and insomnia: a systematic review and meta-analysis of randomized controlled trials, Neuroscience & Biobehavioral Reviews, May 2021, Elsevier,
DOI: 10.1016/j.neubiorev.2021.04.034.
You can read the full text:
Contributors
The following have contributed to this page